NCT02787369 2026-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Clinical Trials
5 trialsNCT02091063 2024-08-06
ACY-1215 for Relapsed/Refractory Lymphoid Malignancies
Columbia University
Phase 1/2 Terminated
NCT02632071 2021-01-07
ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer
Columbia University
Phase 1 Completed
NCT02661815 2019-11-08
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT02856568 2017-05-30
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Withdrawn